Syndax Pharmaceuticals SNDX Increase (Decrease) in Accounts Receivable and Other Operating Assets
Increase (Decrease) in Accounts Receivable and Other Operating Assets at other companies
Other financials
Where this comes from
Reported directly by Syndax Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets.
The official record: Syndax Pharmaceuticals’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Syndax Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Syndax Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets?
- Syndax Pharmaceuticals (SNDX) reported increase (decrease) in accounts receivable and other operating assets of -$6.14M in Q1 2026.
- How has Syndax Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets changed year-over-year?
- Syndax Pharmaceuticals's increase (decrease) in accounts receivable and other operating assets decreased by 13537.8% year-over-year, from -$45K to -$6.14M.